WO2021229480A1 - Polymorph of rifaximin, process for the preparation thereof and pharmaceutical composition containing rifaximin - Google Patents
Polymorph of rifaximin, process for the preparation thereof and pharmaceutical composition containing rifaximin Download PDFInfo
- Publication number
- WO2021229480A1 WO2021229480A1 PCT/IB2021/054078 IB2021054078W WO2021229480A1 WO 2021229480 A1 WO2021229480 A1 WO 2021229480A1 IB 2021054078 W IB2021054078 W IB 2021054078W WO 2021229480 A1 WO2021229480 A1 WO 2021229480A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- rifaximin
- pharmaceutical composition
- polymorphic form
- optionally
- cellulose
- Prior art date
Links
- NZCRJKRKKOLAOJ-XRCRFVBUSA-N rifaximin Chemical compound OC1=C(C(O)=C2C)C3=C4N=C5C=C(C)C=CN5C4=C1NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@H](C)[C@@H](OC)\C=C\O[C@@]1(C)OC2=C3C1=O NZCRJKRKKOLAOJ-XRCRFVBUSA-N 0.000 title claims abstract description 121
- 229960003040 rifaximin Drugs 0.000 title claims abstract description 113
- 238000000034 method Methods 0.000 title claims abstract description 36
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 36
- 238000002360 preparation method Methods 0.000 title claims abstract description 18
- 238000000634 powder X-ray diffraction Methods 0.000 claims description 29
- 239000000203 mixture Substances 0.000 claims description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 20
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 19
- 235000019441 ethanol Nutrition 0.000 claims description 11
- 238000002425 crystallisation Methods 0.000 claims description 10
- 239000003937 drug carrier Substances 0.000 claims description 10
- 238000001157 Fourier transform infrared spectrum Methods 0.000 claims description 9
- 230000008025 crystallization Effects 0.000 claims description 9
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 9
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 9
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 9
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 9
- 239000002904 solvent Substances 0.000 claims description 9
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 8
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 8
- 239000000725 suspension Substances 0.000 claims description 8
- 239000011248 coating agent Substances 0.000 claims description 7
- 239000008109 sodium starch glycolate Substances 0.000 claims description 7
- 229920003109 sodium starch glycolate Polymers 0.000 claims description 7
- 229940079832 sodium starch glycolate Drugs 0.000 claims description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 6
- 229920001223 polyethylene glycol Polymers 0.000 claims description 6
- 239000007787 solid Substances 0.000 claims description 6
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 5
- 239000008187 granular material Substances 0.000 claims description 5
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 5
- 239000000314 lubricant Substances 0.000 claims description 5
- 229920005862 polyol Polymers 0.000 claims description 5
- 150000003077 polyols Chemical class 0.000 claims description 5
- 239000000454 talc Substances 0.000 claims description 5
- 229910052623 talc Inorganic materials 0.000 claims description 5
- ORLGLBZRQYOWNA-UHFFFAOYSA-N 4-methylpyridin-2-amine Chemical compound CC1=CC=NC(N)=C1 ORLGLBZRQYOWNA-UHFFFAOYSA-N 0.000 claims description 4
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 4
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 4
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 claims description 4
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 4
- 239000002202 Polyethylene glycol Substances 0.000 claims description 4
- RAFHKEAPVIWLJC-OQQFTUDCSA-N Rifamycin O Natural products COC1C=COC2(C)Oc3c(C)c(O)c4C(=O)C(=CC5(OCC(=O)O5)c4c3C2=O)NC(=O)C(=C/C=C/C(C)C(O)C(C)C(O)C(C)C(OC(=O)C)C1C)C RAFHKEAPVIWLJC-OQQFTUDCSA-N 0.000 claims description 4
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 4
- 229950011175 aminopicoline Drugs 0.000 claims description 4
- 239000002738 chelating agent Substances 0.000 claims description 4
- 238000000576 coating method Methods 0.000 claims description 4
- 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 claims description 4
- 239000000796 flavoring agent Substances 0.000 claims description 4
- FETSQPAGYOVAQU-UHFFFAOYSA-N glyceryl palmitostearate Chemical compound OCC(O)CO.CCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O FETSQPAGYOVAQU-UHFFFAOYSA-N 0.000 claims description 4
- 229940046813 glyceryl palmitostearate Drugs 0.000 claims description 4
- 229960003943 hypromellose Drugs 0.000 claims description 4
- 235000019359 magnesium stearate Nutrition 0.000 claims description 4
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 4
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 4
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 4
- -1 selected from Substances 0.000 claims description 4
- 239000000377 silicon dioxide Substances 0.000 claims description 4
- 235000010356 sorbitol Nutrition 0.000 claims description 4
- 239000000600 sorbitol Substances 0.000 claims description 4
- 239000004094 surface-active agent Substances 0.000 claims description 4
- 239000003765 sweetening agent Substances 0.000 claims description 4
- RAFHKEAPVIWLJC-TWYIRNIGSA-N z67lem9p1w Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)N2)C)OC)C(C(=C3O)C)=C1C1=C3C(=O)C2=C[C@]11OCC(=O)O1 RAFHKEAPVIWLJC-TWYIRNIGSA-N 0.000 claims description 4
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 3
- 239000001856 Ethyl cellulose Substances 0.000 claims description 3
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 3
- 229930195725 Mannitol Natural products 0.000 claims description 3
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 3
- 235000010980 cellulose Nutrition 0.000 claims description 3
- 229920002678 cellulose Polymers 0.000 claims description 3
- 239000001913 cellulose Substances 0.000 claims description 3
- 229920002301 cellulose acetate Polymers 0.000 claims description 3
- 239000002274 desiccant Substances 0.000 claims description 3
- 239000007884 disintegrant Substances 0.000 claims description 3
- 235000019325 ethyl cellulose Nutrition 0.000 claims description 3
- 229920001249 ethyl cellulose Polymers 0.000 claims description 3
- 235000011187 glycerol Nutrition 0.000 claims description 3
- 239000000594 mannitol Substances 0.000 claims description 3
- 235000010355 mannitol Nutrition 0.000 claims description 3
- 239000002304 perfume Substances 0.000 claims description 3
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 3
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 3
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims description 3
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 2
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 claims description 2
- 229920002785 Croscarmellose sodium Polymers 0.000 claims description 2
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 2
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 claims description 2
- 239000008116 calcium stearate Substances 0.000 claims description 2
- 235000013539 calcium stearate Nutrition 0.000 claims description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims description 2
- 229960000913 crospovidone Drugs 0.000 claims description 2
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims description 2
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 claims description 2
- 235000003599 food sweetener Nutrition 0.000 claims description 2
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims description 2
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 claims description 2
- 239000008213 purified water Substances 0.000 claims description 2
- 229940045902 sodium stearyl fumarate Drugs 0.000 claims description 2
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 claims 1
- 239000004150 EU approved colour Substances 0.000 claims 1
- 229960001681 croscarmellose sodium Drugs 0.000 claims 1
- 239000008172 hydrogenated vegetable oil Substances 0.000 claims 1
- 239000002480 mineral oil Substances 0.000 claims 1
- 229940006093 opthalmologic coloring agent diagnostic Drugs 0.000 claims 1
- 239000003826 tablet Substances 0.000 description 15
- 239000006186 oral dosage form Substances 0.000 description 7
- 238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 239000004480 active ingredient Substances 0.000 description 6
- 238000001228 spectrum Methods 0.000 description 6
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 229920002472 Starch Polymers 0.000 description 4
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 4
- 230000003115 biocidal effect Effects 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- MMXKVMNBHPAILY-UHFFFAOYSA-N ethyl laurate Chemical compound CCCCCCCCCCCC(=O)OCC MMXKVMNBHPAILY-UHFFFAOYSA-N 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 238000005160 1H NMR spectroscopy Methods 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- 238000002441 X-ray diffraction Methods 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 239000007795 chemical reaction product Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 229920001817 Agar Polymers 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241000416162 Astragalus gummifer Species 0.000 description 2
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 2
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 2
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical class CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 2
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 229920001615 Tragacanth Polymers 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 2
- 229910021502 aluminium hydroxide Inorganic materials 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 239000006172 buffering agent Substances 0.000 description 2
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 2
- 229940095259 butylated hydroxytoluene Drugs 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000012876 carrier material Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 229960001484 edetic acid Drugs 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 2
- 229940093471 ethyl oleate Drugs 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 150000002334 glycols Chemical class 0.000 description 2
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 2
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 2
- 229920000639 hydroxypropylmethylcellulose acetate succinate Polymers 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000007937 lozenge Substances 0.000 description 2
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 2
- 239000000347 magnesium hydroxide Substances 0.000 description 2
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000000704 physical effect Effects 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 229920001592 potato starch Polymers 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- HJYYPODYNSCCOU-ODRIEIDWSA-N rifamycin SV Chemical class OC1=C(C(O)=C2C)C3=C(O)C=C1NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@H](C)[C@@H](OC)\C=C\O[C@@]1(C)OC2=C3C1=O HJYYPODYNSCCOU-ODRIEIDWSA-N 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 239000007962 solid dispersion Substances 0.000 description 2
- 229940032147 starch Drugs 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 235000010487 tragacanth Nutrition 0.000 description 2
- 239000000196 tragacanth Substances 0.000 description 2
- 229940116362 tragacanth Drugs 0.000 description 2
- XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical compound [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 description 2
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 2
- QIJRTFXNRTXDIP-UHFFFAOYSA-N (1-carboxy-2-sulfanylethyl)azanium;chloride;hydrate Chemical compound O.Cl.SCC(N)C(O)=O QIJRTFXNRTXDIP-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 206010012742 Diarrhoea infectious Diseases 0.000 description 1
- 208000012258 Diverticular disease Diseases 0.000 description 1
- 206010013554 Diverticulum Diseases 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 229920003135 Eudragit® L 100-55 Polymers 0.000 description 1
- 238000004566 IR spectroscopy Methods 0.000 description 1
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 description 1
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical class CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 229930189077 Rifamycin Natural products 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- ZUAAPNNKRHMPKG-UHFFFAOYSA-N acetic acid;butanedioic acid;methanol;propane-1,2-diol Chemical compound OC.CC(O)=O.CC(O)CO.OC(=O)CCC(O)=O ZUAAPNNKRHMPKG-UHFFFAOYSA-N 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 229940087168 alpha tocopherol Drugs 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 229940126575 aminoglycoside Drugs 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000012296 anti-solvent Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 235000010385 ascorbyl palmitate Nutrition 0.000 description 1
- 235000019282 butylated hydroxyanisole Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 239000007891 compressed tablet Substances 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229920001531 copovidone Polymers 0.000 description 1
- 239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 description 1
- 229960001305 cysteine hydrochloride Drugs 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 208000007386 hepatic encephalopathy Diseases 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 230000000266 injurious effect Effects 0.000 description 1
- 208000002551 irritable bowel syndrome Diseases 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 235000010603 pastilles Nutrition 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229940057838 polyethylene glycol 4000 Drugs 0.000 description 1
- 229920000193 polymethacrylate Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 239000000473 propyl gallate Substances 0.000 description 1
- 235000010388 propyl gallate Nutrition 0.000 description 1
- 229940075579 propyl gallate Drugs 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 229960003292 rifamycin Drugs 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 206010040872 skin infection Diseases 0.000 description 1
- WBHQBSYUUJJSRZ-UHFFFAOYSA-M sodium bisulfate Chemical compound [Na+].OS([O-])(=O)=O WBHQBSYUUJJSRZ-UHFFFAOYSA-M 0.000 description 1
- 229910000342 sodium bisulfate Inorganic materials 0.000 description 1
- 229940100996 sodium bisulfate Drugs 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 229940001584 sodium metabisulfite Drugs 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 229940001482 sodium sulfite Drugs 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000007916 tablet composition Substances 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229960000984 tocofersolan Drugs 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 239000002076 α-tocopherol Substances 0.000 description 1
- 235000004835 α-tocopherol Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
Definitions
- WO2012156951 discloses polymorphous forms of Rifaximin namely Form kappa. The said form tends to keep its crystalline form even in the presence of moisture thereby making it more stable.
- WO2012109605 discloses polymorphous forms of Rifaximin namely Form Mu, Form Pis, Form Omicron, Form Zeta, Form Eta, Form Iota, and salt forms and hydrates of Rifaximin.
- WO2011156897 discloses polymorphous forms of Rifaximin namely substantially pure APO-I and ⁇ -II, are provided. Rifaximin dissolved in ethyl acetate is added to heptanes to obtain form APO-I.
- WO 2008155728 describes a process which provides Rifaximin in a completely amorphous form. Said process comprises the steps of dissolving crude Rifaximin in absolute ethanol while hot and then collecting after precipitation by cooling to obtain Rifaximin in amorphous form.
- WO2008035109 discloses amorphous Rifaximin, methods of making it, and pharmaceutical compositions containing it Also described are methods of converting amorphous Rifaximin to crystalline Rifaximin and vice versa.
- US 20090082558 describes a stable amorphous form of Rifaximin. This form is chemically and polymorphic stable on storage and can be prepared by dissolving Rifaximin in a solvent to form a solution which is precipitated by adding an antisolvent and isolating of the precipitated amorphous Rifaximin as an end product.
- WO2006094737 and WO2012038898 describes a pharmaceutical composition comprising gastro-resistant Rifaximin microgranules.
- WO2011051971 describes a solid dispersion of Rifaximin comprising Rifaximin and pharmaceutically acceptable carrier, wherein the pharmaceutically acceptable carrier comprises copovidone and polyethylene glycol.
- WO2012009387 describes a solid dispersion that comprises Rifaximin and one or more polymers selected from hydroxypropyl methylcellulose phthalate (HPMC-P), hydroxypropyl methylcellulose acetate succinate (HPMC-AS), and a polymethacrylate (Eudragit® L100-55) in a specific ratio.
- HPMC-P hydroxypropyl methylcellulose phthalate
- HPMC-AS hydroxypropyl methylcellulose acetate succinate
- Eudragit® L100-55 polymethacrylate
- WO2008029208 describes polyols which stabilize polymorphous forms of Rifaximin, in particular the beta form.
- polyols having at least two hydroxyl groups are added to Rifaximin powder, polymorph beta is stable and remains stable in time independently from the environment humidity.
- a method to prepare formulations constituted by pure and stable polymorphous forms able to give a pharmaceutical product is also described.
- WO2011005388, WO2009108814 and WO2011032085 describes use of Rifaximin for the preparation of a medication.
- the present inventors have now identified a novel polymorphic form of Rifaximin, which is stable chemically and polymorphically on storage and is unaffected by external parameters such as ambient humidity.
- the present invention relates to a novel crystalline form of Rifaximin, namely polymorphic form of Rifaximin termed herein as Form RV-A, method for its preparation, pharmaceutical composition containing the novel polymorph of Rifaximin and a method of preparing the pharmaceutical composition.
- An embodiment of the present invention provides the novel polymorphic form RV-A of Rifaximin described herein characterized by a PXRD diffractogram comprising peaks, in terms of degrees 2-theta (+/- 0.20 degree theta) at approximately 5.94, 7.32, 7.92, 8.56 and 19.01.
- An embodiment of the present invention provides the novel polymorphic form RV-A of Rifaximin described herein characterized by a 1 % KBr FTIR spectrum comprising peaks, in terms of cm-1, at approximately 3424, 2920, 1725, 1648 and 1229.
- An embodiment of the present invention provides a pharmaceutical composition comprising the novel polymorphic form RV-A of Rifaximin characterized by a PXRD diffractogram comprising peaks, in terms of degrees 2-theta (+/- 0.20 degree theta) at approximately 5.94, 7.34, 7.93, 8.63, 13.49, 14.49 and 22.47.
- An embodiment of the present invention provides the polymorphic form RV- A of Rifaximin described herein characterized by a PXRD diffractogram substantially similar to the PXRD diffractogram as depicted in Figure 1.
- An embodiment of the present invention provides the polymorphic form RV- A of Rifaximin described herein characterized by a PXRD diffractogram as depicted in Figure 1.
- An embodiment of the present invention provides the polymorphic form RV- A of Rifaximin described herein characterized by a FTIR spectrum substantially similar to the FTIR spectrum as depicted in Figure -2.
- An embodiment of the present invention provides a pharmaceutical composition as an oral dosage form containing the novel polymorphic form RV-A of Rifaximin characterized by a PXRD diffractogram substantially similar to the PXRD diffractogram as depicted in Figure 3.
- An embodiment of the present invention provides a pharmaceutical composition as an oral dosage form containing the novel polymorphic form RV-A of Rifaximin characterized by a PXRD diffractogram as depicted in Figure 3.
- An embodiment of the present invention provides a pharmaceutical composition as an oral dosage form.
- An embodiment of the present invention provides a pharmaceutical composition as an oral dosage form, preferably in the form of a tablet
- a pharmaceutical composition in the form of tablets comprising i) containing Rifaximin RV-A, ii) pharmaceutically acceptable carriers, and optionally iii) a film- forming coating.
- novel polymorph of Rifaximin contain less than 5% by weight total impurities.
- the composition further comprises one or more pharmaceutically acceptable excipients.
- the excipients may be one or more of a diluting agent, binding agent, lubricating agent, disintegrating agent, colouring agent, flavouring agent or sweetening agent [0041]
- An embodiment of the present invention provides a process for the preparation of pharmaceutical composition that is preferably in the form of a tablet [0042]
- a further embodiment of the present invention provides a method for preparing a tablet comprising the steps of
- Figure 4 is a powder X-ray diffraction (PXRD) diffractogram of pharmaceutical composition containing novel polymorphic form RV-A taken after 24 months maintained at 30 °C and 75% relative humidity.
- PXRD powder X-ray diffraction
- Embodiments of the present invention relates to novel polymorphic form of Rifaximin, process for the preparation of the novel polymorphic form, pharmaceutical composition containing the novel polymorphic form as well as to a process of preparing the pharmaceutical composition containing the novel polymorphic form.
- Rifaximin Form RV-A As used herein "Rifaximin Form RV-A”, “Form RV-A”, “polymorph RV-A”, “Form RV-A of Rifaximin” are used interchangeably to denote the polymorphic form of Rifaximin as further described herein by, for example, one or more peaks of a powder x-ray diffractogram, NMR, FT-IR.
- Rifaximin form RV-A comprises powder x- ray diffraction pattern peak positions described herein and in the figures.
- Rifaximin form RV-A may be identified and characterised by one or more of these parameters or peaks.
- Polymorphs are distinct solids sharing the same molecular formula, yet each polymorph may have distinct physical properties. Therefore, a single compound may give rise to a variety of polymorphic forms where each form has different and distinct physical properties, such as solubility profiles, melting point temperatures, hygroscopicity, particle shape, density, flowability, compatibility and/or x-ray diffraction peaks.
- the solubility of each polymorph may vary, thus, identifying the existence of pharmaceutical polymorphs is essential for providing pharmaceuticals with predictable solubility profiles. It is desirable to investigate all solid-state forms of a drug, including all polymorphic forms, and to determine the stability, dissolution, and flow properties of each polymorphic form.
- Polymorphic forms of a compound can be distinguished in a laboratory by X-ray diffraction spectroscopy and by other methods such as, infrared spectrometry.
- X-ray diffraction spectroscopy and by other methods such as, infrared spectrometry.
- polymorphs and the pharmaceutical applications of polymorphs see G. M. Wall, Pharm Manuf.3, 33 (1986); J. K. Haleblian and W. McCrone, J Pharm. ScL, 58, 911 (1969); and J. K. Haleblian, J. Pharm. ScL, 64, 1269 (1975), all of which are incorporated herein by reference.
- polymorph is occasionally used as a general term in reference to the forms of Rifaximin and includes within the context, salt, hydrate, polymorph and amorphous forms of Rifaximin disclosed herein. This use depends on context and will be clear to one of skill in the art.
- pharmaceutically-acceptable carrier includes pharmaceutically- acceptable material, composition or vehicle, such as a liquid or solid filler, diluent, excipient, solvent or encapsulating material, involved in carrying or transporting the subject chemical from one organ, or portion of the body, to another organ, or portion of the body.
- Each carrier is preferably “acceptable” in the sense of being compatible with the other ingredients of the formulation and not injurious to the subject.
- materials which can serve as pharmaceutically-acceptable carriers include: sugars, such as lactose, glucose and sucrose; starches, such as com starch and potato starch; cellulose, and its derivatives, such as hydroxypropyl methylcellulose (hypromellose), sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; powdered tragacanth; malt; gelatin; talc; glycols, such as propylene glycol; polyols, such as glycerin, sorbitol, mannitol and polyethylene glycol; esters, such as ethyl oleate and ethyl laurate; agar; buffering agents, such as magnesium hydroxide and aluminium hydroxide; lubricants, such as Magnesium stearate, Zinc stearate and Glyceryl palmitostearate; surfactant, such as Sodium lauryl sulfate and Polyethene glycol,
- antioxidants examples include: water soluble antioxidants, such as ascorbic acid, cysteine hydrochloride, sodium bisulfate, sodium metabisulfite, sodium sulfite and the like; oil-soluble antioxidants, such as ascorbyl palmitate, butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), lecithin, propyl gallate, alpha-tocopherol, and the like; and metal chelating agents, such as citric acid, ethylenediamine tetra acetic acid (EDTA), sorbitol, tartaric acid, phosphoric acid, and the like.
- water soluble antioxidants such as ascorbic acid, cysteine hydrochloride, sodium bisulfate, sodium metabisulfite, sodium sulfite and the like
- oil-soluble antioxidants such as ascorbyl palmitate, butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), lecit
- compositions containing novel Rifaximin form RV-A disclosed herein include those suitable for oral, nasal, topical (including buccal and sublingual), rectal, vaginal, aerosol and/or parenteral administration.
- the compositions may conveniently be presented in unit dosage form and may be prepared by any methods well known in the art of pharmacy.
- the amount of active ingredient which can be combined with a carrier material to produce a single dosage form will vary depending upon the host being treated, the particular mode of administration.
- the amount of active ingredient which can be combined with a carrier material to produce a single dosage form will generally be that amount of the compound which produces a therapeutic effect Generally, out of 100 % , this amount will range from about 1 % to about 99 % of active ingredient, preferably from about 5 % to about 70 %, most preferably from about 10 % to about 60 %.
- Methods of preparing these compositions include the step of bringing into association the novel Rifaximin polymorph with the carrier and, optionally, one or more accessory ingredients.
- compositions suitable for oral administration may be in the form of capsules, sachets, pills, tablets, lozenges, powders, granules, or as a solution or a suspension in an aqueous or non-aqueous liquid, or as an oil-in-water or water-in-oil liquid emulsion, or as an elixir or syrup, or as pastilles and the like, each containing a predetermined amount of the Rifaximin polymorph as an active ingredient
- a compound may also be administered as a bolus, electuary or paste.
- a tablet may be made by compression or moulding, optionally with one or more accessory ingredients.
- Compressed tablets may be prepared using binder such as gelatin or hydroxypropylmethyl cellulose and the like; lubricant; inert diluent; preservative; dis-integrant such as sodium starch glycolate or cross-linked sodium carboxymethyl cellulose and the like; surface-active or dispersing agent.
- Moulded tablets may be made by moulding a mixture of the powdered active ingredient moistened with an inert liquid diluent in a suitable machine.
- the tablets, and other solid dosage forms of the pharmaceutical compositions described herein may optionally be scored or prepared with coatings and shells, such as enteric coatings and other coatings well known in the pharmaceutical- formulating art They may also be formulated so as to provide slow or controlled release of the active ingredient therein using, for example, hydroxypropylmethyl cellulose in varying proportions to provide the desired release profile, other polymer matrices, liposomes and/ or microspheres.
- An embodiment of the present invention provides the novel polymorphic form RV-A of Rifaximin described herein characterized by a PXRD diffractogram comprising peaks, in terms of degrees 2-theta (+/- 0.20 degree theta) at approximately 5.94, 7.32, 7.92, 8.56 and 19.01.
- An embodiment of the present invention provides the novel polymorphic form RV-A of Rifaximin described herein characterized by a 1 % KBr FITR spectrum comprising peaks, in terms of cm-1, at approximately 3424, 2920, 1725, 1648 and 1229.
- An embodiment of the present invention provides a process for the preparation of a polymorphic form RV-A of Rifaximin, the process comprising: a.
- the resulting crude Rifaximin is purified by dissolving alcohol preferable ethyl alcohol, at a temperature between 35°C and 75°C, followed by crystallization by addition of water.
- the resulting suspension is stirred at a temperature between 50°C and 0°C for a duration between 2 and 24 hours.
- the suspension is filtered and the obtained solid is washed with water and dried under vacuum, optionally in the presence of a drying agent, at a temperature between room temperature and 75°C for a time between 2 and 24 hours.
- An embodiment of the present invention provides a pharmaceutical composition as an oral dosage form, preferably in the form of a tablet [0069]
- An embodiment of the present invention provides a pharmaceutical composition in the form of tablets comprising i) Rifaximin RV-A, ii) pharmaceutically acceptable carriers, and optionally iii) a film forming coating agent.
- the pharmaceutically acceptable carriers comprise sugars, such as lactose, glucose and sucrose; starches, such as com starch and potato starch; cellulose and its derivatives, such as hydroxypropyl methylcellulose (hypromellose), sodium carboxymethyl cellulose, carboxymethyl cellulose, microcrystalline cellulose, ethyl cellulose, sodium starch glycolate and cellulose acetate; powdered tragacanth; malt; gelatin; talc; glycols, such as propylene glycol; polyols, such as glycerin, sorbitol, mannitol and polyethylene glycol; esters, such as ethyl oleate and ethyl laurate; agar; buffering agents, such as magnesium hydroxide and aluminium hydroxide; lubricants, such as Magnesium stearate, Zinc stearate, Calcium stearate, Sodium stearyl fumarate, Vegetable hydrogenated oil and Glyce
- An embodiment of the present invention provides a pharmaceutical composition comprising the novel polymorphic form RV-A of Rifaximin characterized by a PXRD diffractogram comprising peaks, in terms of degrees 2-theta (+/- 0.20 degree theta) at approximately 5.94, 7.34, 7.93, 8.63, 14.49 and 22.47.
- An embodiment of the present invention provides a pharmaceutical composition comprising the novel polymorphic form RV-A of Rifaximin which is stable over 24 months even when maintained at 30°Cand 75% relative humidity characterized by a PXRD diffractogram comprising peaks, in terms of degrees 2-theta (+/- 0.20 degree theta) at approximately 5.92, 7.35, 7.92, 8.60, 14.49 and 22.51.
- Powder X-ray diffraction (PXRD) analysis was performed using Bruker D8 Advance LYNXEYE XE-T diffractometer.
- FTIR Fourier Transform Infrared
- Rifaximin form RV-A was characterised by powder X- ray diffractogram showing significant peaks at diffraction angles 2 ⁇ of 5.94°; 7.32°; 7.92°
- a Rifaximin composition comprising the novel polymorphic form of Rifaximin namely RV-A, microcrystalline cellulose, sodium starch glycolate, polyethylene glycol 4000, hypromellose, disodium EDTA and purified water, was mixed in a rapid mixer granulator for 15 minutes at slow speed. The blended wet mass was dried in a fluid bed dryer to obtain granules that had a moisture content of up to 4% . The granules obtained were mixed with microcrystalline cellulose, sodium starch glycolate, purified talc, colloidal anhydrous silica, glyceryl palmito stearate and magnesium stearate in a blender. The final blend was compressed on a press and the resulting tablets were film coated with instacoat Universal A05R00959 such that the resulting tablets each contain Rifaximin 555.5 mg including 1% overage and the overall tablet weight is 980 mg ⁇ 5% .
Abstract
The present invention relates to a novel polymorphic form of Rifaximin designated RV-A, method for its preparation, pharmaceutical composition containing the novel polymorphic form of Rifaximin and a method of preparing the pharmaceutical composition.
Description
POLYMORPH OF RIFAXIMIN, PROCESS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION
CONTAINING RIFAXIMIN
TECHNICAL FIELD
[001] The present invention relates to a novel polymorphic form of Rifaximin, method for its preparation, pharmaceutical composition containing the novel polymorphic form of Rifaximin and a method of preparing the pharmaceutical composition.
BACKGROUND
[002] Rifaximin is an antibiotic belonging to the rifamycin class. Rifaximin (1) is a non-aminoglycoside semi-synthetic, non-systemic antibiotic derived from Rifamycin, useful for the treatment of traveller's diarrhoea caused by Escherichia coli bacteria. Rifaximin has also been evaluated for the treatment of irritable bowel syndrome, diverticular disease, hepatic encephalopathy, pyogenic skin infections, and as an antibacterial prophylactic prior to colon surgery.
[003] Chemically, Rifaximin is (2S, 16Z, 18E, 20S, 21 S, 22R, 23R, 24R, 25S, 26S, 27S, 28E)-5, 6, 21, 23, 25-pentahydroxy- 27-methoxy-2, 4, 11, 16, 20, 22, 24, 26-octamethyl- 2,7-(epoxypentadeca-[1 ,1 1 ,13]trienimino)- benzofuro[4,5-e]-pyrido[l , 2-(a)]- benzimidazole-1 , 15(2H)dione, 25-acetate.
[004] WO2005044823 discloses crystalline polymorphous forms of Rifaximin (INN) antibiotic named Rifaximin alpha and Rifaximin beta, and a poorly crystalline form with a high content of amorphous content named Rifaximin gamma. These forms can be obtained by means of a crystallization process carried out by hot-dissolving the raw Rifaximin in ethyl alcohol and by causing the crystallization of the product by the addition of water at a determinate temperature and for a determinate time period. The crystallization is followed by drying carried out under controlled conditions until specific water content is reached in the end product Also described is a composition comprising substantially amorphous Rifaximin, and a method of preparing amorphous Rifaximin. The method comprises providing dried Rifaximin; heating the Rifaximin in the presence of an alcohol to result in dissolution of the Rifaximin; precipitating and drying the precipitate to have a water content of less than 2% to form substantially amorphous Rifaximin. The disclosure further relates to Rifaximin polymorphic forms alpha, beta and gamma, the processes for their preparation and the use thereof in the manufacture of medicinal preparations for the oral or topical route.
[005] WO2006094662 disclose crystalline polymorphous forms of Rifaximin (INN) antibiotic named Rifaximin delta and Rifaximin epsilon. These forms can be obtained by means of a crystallization process carried out by hot-dissolving the raw Rifaximin in ethyl alcohol and by causing the crystallization of the product by addition of water at a determinate temperature and for a determinate time period. The crystallization is followed by drying carried out under controlled conditions until specific water content is reached in the end product.
[006] WO 2009108730 and WO2011103120 relates to Rifaximin polymorphic, salt, hydrate, and amorphous forms, to their use in medicinal preparations, and to therapeutic methods using them. Form zeta, Form eta, Form alpha-dry, Form iota, Form iota-dry, Form iota-dry', Form beta-1, Form beta-2, Form epsilon-dry, Form B and amorphous forms of Rifaximin as well as a mesylate salt are described.
[007] WO2012156951 discloses polymorphous forms of Rifaximin namely Form kappa. The said form tends to keep its crystalline form even in the presence of moisture thereby making it more stable.
[008] WO2012109605 discloses polymorphous forms of Rifaximin namely Form Mu, Form Pis, Form Omicron, Form Zeta, Form Eta, Form Iota, and salt forms and hydrates of Rifaximin.
[009] WO2011156897 discloses polymorphous forms of Rifaximin namely substantially pure APO-I and ΑΡΟ-II, are provided. Rifaximin dissolved in ethyl acetate is added to heptanes to obtain form APO-I.
[0010] WO2013185211 discloses polymorphous forms of Rifaximin named ΑΡΟ-III and APO-IV. Also provided are novel processes for preparing the previously disclosed Rifaximin polymorphic forms APO-I and ΑΡΟ-II.
[0011] WO 2008155728 describes a process which provides Rifaximin in a completely amorphous form. Said process comprises the steps of dissolving crude Rifaximin in absolute ethanol while hot and then collecting after precipitation by cooling to obtain Rifaximin in amorphous form.
[0012] WO2008035109 discloses amorphous Rifaximin, methods of making it, and pharmaceutical compositions containing it Also described are methods of converting amorphous Rifaximin to crystalline Rifaximin and vice versa.
[0013] US 20090082558 describes a stable amorphous form of Rifaximin. This form is chemically and polymorphic stable on storage and can be prepared by dissolving Rifaximin in a solvent to form a solution which is precipitated by adding an antisolvent and isolating of the precipitated amorphous Rifaximin as an end product. [0014] WO2006094737 and WO2012038898 describes a pharmaceutical composition comprising gastro-resistant Rifaximin microgranules.
[0015] WO2011051971 describes a solid dispersion of Rifaximin comprising Rifaximin and pharmaceutically acceptable carrier, wherein the pharmaceutically acceptable carrier comprises copovidone and polyethylene glycol.
[0016] WO2012009387 describes a solid dispersion that comprises Rifaximin and one or more polymers selected from hydroxypropyl methylcellulose phthalate (HPMC-P), hydroxypropyl methylcellulose acetate succinate (HPMC-AS), and a polymethacrylate (Eudragit® L100-55) in a specific ratio.
[0017] WO2008029208 describes polyols which stabilize polymorphous forms of Rifaximin, in particular the beta form. When polyols having at least two hydroxyl
groups are added to Rifaximin powder, polymorph beta is stable and remains stable in time independently from the environment humidity. A method to prepare formulations constituted by pure and stable polymorphous forms able to give a pharmaceutical product is also described.
[0018] WO2011005388, WO2009108814 and WO2011032085 describes use of Rifaximin for the preparation of a medication.
[0019] The present inventors have now identified a novel polymorphic form of Rifaximin, which is stable chemically and polymorphically on storage and is unaffected by external parameters such as ambient humidity.
SUMMARY
[0020] The present invention relates to a novel crystalline form of Rifaximin, namely polymorphic form of Rifaximin termed herein as Form RV-A, method for its preparation, pharmaceutical composition containing the novel polymorph of Rifaximin and a method of preparing the pharmaceutical composition.
[0021] An embodiment of the present invention provides the novel polymorphic form RV-A of Rifaximin described herein characterized by a PXRD diffractogram comprising peaks, in terms of degrees 2-theta (+/- 0.20 degree theta) at approximately 5.94, 7.32, 7.92, 8.56 and 19.01.
[0022] An embodiment of the present invention provides the novel polymorphic form RV-A of Rifaximin described herein characterized by a 1 % KBr FTIR spectrum comprising peaks, in terms of cm-1, at approximately 3424, 2920, 1725, 1648 and 1229. [0023] An embodiment of the present invention provides a pharmaceutical composition comprising the novel polymorphic form RV-A of Rifaximin characterized by a PXRD diffractogram comprising peaks, in terms of degrees 2-theta (+/- 0.20 degree theta) at approximately 5.94, 7.34, 7.93, 8.63, 13.49, 14.49 and 22.47.
[0024] An embodiment of the present invention provides the polymorphic form RV- A of Rifaximin described herein characterized by a PXRD diffractogram substantially similar to the PXRD diffractogram as depicted in Figure 1.
[0025] An embodiment of the present invention provides the polymorphic form RV- A of Rifaximin described herein characterized by a PXRD diffractogram as depicted in Figure 1.
[0026] An embodiment of the present invention provides the polymorphic form RV- A of Rifaximin described herein characterized by a FTIR spectrum substantially similar to the FTIR spectrum as depicted in Figure -2.
[0027] An embodiment of the present invention provides the polymorphic form RV- A of Rifaximin described herein characterized by a FTIR spectrum as depicted in Figure 2.
[0028] An embodiment of the present invention provides a pharmaceutical composition as an oral dosage form containing the novel polymorphic form RV-A of Rifaximin characterized by a PXRD diffractogram substantially similar to the PXRD diffractogram as depicted in Figure 3.
[0029] An embodiment of the present invention provides a pharmaceutical composition as an oral dosage form containing the novel polymorphic form RV-A of Rifaximin characterized by a PXRD diffractogram as depicted in Figure 3.
[0030] An embodiment of the present invention provides a pharmaceutical composition as an oral dosage form containing the novel polymorphic form RV-A of Rifaximin that is stable over 24 months characterized by a PXRD diffractogram substantially similar to the PXRD diffractogram as depicted in Figure 4.
[0031] An embodiment of the present invention provides a pharmaceutical composition as an oral dosage form containing the novel polymorphic form RV-A of Rifaximin that is stable over 24 months characterized by a PXRD diffractogram as depicted in Figure 4.
[0032] An embodiment of the present invention provides a process for the preparation of a polymorphic form RV-A of Rifaximin, the process comprising: a. Reacting rifamycin O with 2-amino-4-methylpyridine in a suitable solvent or a mixture of solvents, for a time between 2 - 10 hours and at a temperature between 25°C to 75°C to provide crude Rifaximin, b. The resulting crude Rifaximin is purified by dissolving alcohol preferable ethyl alcohol, at a temperature between 35°C and 75°C, followed by crystallization
by addition of water. The resulting suspension is stirred at a temperature between 50°C and 0°C for a duration between 2 and 24 hours, c. The suspension is filtered and the obtained solid is washed with water and dried under vacuum, optionally in the presence of a drying agent, at a temperature between room temperature and 75°C for a time between 2 and 24 hours.
[0033] An embodiment of the present invention provides a pharmaceutical composition as an oral dosage form.
[0034] According to one embodiment, the pharmaceutical composition may be formulated as coated or uncoated tablets, hard or soft gelatin capsules, sugar-coated pills, lozenges, wafer sheets, pellets or powders in a sealed packet.
[0035] An embodiment of the present invention provides a pharmaceutical composition as an oral dosage form, preferably in the form of a tablet [0036] An embodiment of the present invention provides a pharmaceutical composition in the form of tablets comprising i) containing Rifaximin RV-A, ii) pharmaceutically acceptable carriers, and optionally iii) a film- forming coating.
[0037] In one embodiment the novel polymorph of Rifaximin contain less than 5% by weight total impurities.
[0038] In one embodiment the novel polymorph of Rifaximin is at least 75% pure, or at least 80% pure, or at least 90% pure, or at least 95% pure, or at least 98% pure. [0039] According to one embodiment, the pharmaceutical composition comprises novel polymorph of Rifaximin and a pharmaceutically acceptable carrier.
[0040] In one embodiment, the composition further comprises one or more pharmaceutically acceptable excipients. The excipients may be one or more of a diluting agent, binding agent, lubricating agent, disintegrating agent, colouring agent, flavouring agent or sweetening agent
[0041] An embodiment of the present invention provides a process for the preparation of pharmaceutical composition that is preferably in the form of a tablet [0042] A further embodiment of the present invention provides a method for preparing a tablet comprising the steps of
(i) providing novel polymorph of Rifaximin RV-A and optionally one or more further excipients
(ii) optionally granulating the mixture of step (i) and optionally one or more further excipients
(iii) compressing the mixture from step (i) or the granulates from step (ii) and optionally further excipients into a tablet
[0043] According to another embodiment presented herein, is use of novel polymorph of Rifaximin namely Form RV-A as a medicament [0044] According to another embodiment presented herein, is a process for production of novel polymorph of Rifaximin namely Form RV-A.
BRIEF DESCRIPTION OF THE DRAWINGS
[0045] Drawings which illustrate embodiments of the invention are:
[0046] Figure 1: is a powder X-ray diffraction (PXRD) diffractogram of novel polymorphic form RV-A
[0047] Figure 2: is a Fourier Transform Infrared (FTIR) spectrum of novel polymorphic form RV-A
[0048] Figure 3: is a powder X-ray diffraction (PXRD) diffractogram of pharmaceutical composition containing novel polymorphic form RV-A
[0049] Figure 4: is a powder X-ray diffraction (PXRD) diffractogram of pharmaceutical composition containing novel polymorphic form RV-A taken after 24 months maintained at 30 °C and 75% relative humidity.
DETAILED DESCRIPTION
[0050] Embodiments of the present invention relates to novel polymorphic form of Rifaximin, process for the preparation of the novel polymorphic form, pharmaceutical composition containing the novel polymorphic form as well as to a process of preparing the pharmaceutical composition containing the novel polymorphic form. [0051] As used herein "Rifaximin Form RV-A", "Form RV-A", "polymorph RV-A", "Form RV-A of Rifaximin" are used interchangeably to denote the polymorphic form of Rifaximin as further described herein by, for example, one or more peaks of a powder x-ray diffractogram, NMR, FT-IR. Rifaximin form RV-A comprises powder x- ray diffraction pattern peak positions described herein and in the figures. Rifaximin form RV-A may be identified and characterised by one or more of these parameters or peaks.
[0052] Polymorphs are distinct solids sharing the same molecular formula, yet each polymorph may have distinct physical properties. Therefore, a single compound may give rise to a variety of polymorphic forms where each form has different and distinct physical properties, such as solubility profiles, melting point temperatures, hygroscopicity, particle shape, density, flowability, compatibility and/or x-ray diffraction peaks. The solubility of each polymorph may vary, thus, identifying the existence of pharmaceutical polymorphs is essential for providing pharmaceuticals with predictable solubility profiles. It is desirable to investigate all solid-state forms of a drug, including all polymorphic forms, and to determine the stability, dissolution, and flow properties of each polymorphic form. Polymorphic forms of a compound can be distinguished in a laboratory by X-ray diffraction spectroscopy and by other methods such as, infrared spectrometry. For a general review of polymorphs and the pharmaceutical applications of polymorphs see G. M. Wall, Pharm Manuf.3, 33 (1986); J. K. Haleblian and W. McCrone, J Pharm. ScL, 58, 911 (1969); and J. K. Haleblian, J. Pharm. ScL, 64, 1269 (1975), all of which are incorporated herein by reference.
[0053] When used in reference to a diffractogram, a spectrum and/or data presented in a graph, the term "substantially similar" means that the subject diffractogram, spectrum and/ or data presented in a graph encompasses all diffractograms, spectra and/or data presented in graphs that vary within acceptable boundaries of
experimentation that are known to a person of skill in the art. Such boundaries of experimentation will vary depending on the type of the subject diffractogram, spectrum and/ or data presented in a graph, but will nevertheless be known to a person of skill in the art.
[0054] When used in reference to a peak in a PXRD diffractogram, the term "approximately" means that the peak may vary by ±0.2 degrees 2-theta of the subject value.
[0055] When used in reference to a peak in a FTIR spectrum, the term "approximately" means that the peak may vary by ±5 cm of the subject value.
[0056] As used herein, the term polymorph is occasionally used as a general term in reference to the forms of Rifaximin and includes within the context, salt, hydrate, polymorph and amorphous forms of Rifaximin disclosed herein. This use depends on context and will be clear to one of skill in the art.
[0057] The following example serves to illustrate the present invention in more detail. They are, however, not intended to limit its scope in any manner. Depending on the nature of the methodology applied and the scale selected to display results obtained from an X-ray diffraction analysis, an intensity of a peak obtained may vary quite dramatically. For example, it is possible to obtain a relative peak intensity of 1 % when analyzing one sample of a substance, but another sample of the same substance may show a much different relative intensity for a peak at the same position. This may be due, in part, to the preferred orientation of the sample and its deviation from the ideal random sample orientation, sample preparation and the methodology applied. Such variations are known and understood by a person of skill in the art.
[0058] The phrase "pharmaceutically-acceptable carrier" includes pharmaceutically- acceptable material, composition or vehicle, such as a liquid or solid filler, diluent, excipient, solvent or encapsulating material, involved in carrying or transporting the subject chemical from one organ, or portion of the body, to another organ, or portion of the body. Each carrier is preferably "acceptable" in the sense of being compatible with the other ingredients of the formulation and not injurious to the subject. Some examples of materials which can serve as pharmaceutically-acceptable carriers include: sugars, such as lactose, glucose and sucrose; starches, such as com starch and
potato starch; cellulose, and its derivatives, such as hydroxypropyl methylcellulose (hypromellose), sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; powdered tragacanth; malt; gelatin; talc; glycols, such as propylene glycol; polyols, such as glycerin, sorbitol, mannitol and polyethylene glycol; esters, such as ethyl oleate and ethyl laurate; agar; buffering agents, such as magnesium hydroxide and aluminium hydroxide; lubricants, such as Magnesium stearate, Zinc stearate and Glyceryl palmitostearate; surfactant, such as Sodium lauryl sulfate and Polyethene glycol, chelating agent, such as disodium EDTA; glidant, such as colloidal anhydrous silica and Talc; coating agents; coloring agents; sweetening, flavoring and perfuming agents; pyrogen- free water; isopropyl alcohol; and other non-toxic compatible substances employed in pharmaceutical formulations.
[0059] Examples of pharmaceutically-acceptable antioxidants include: water soluble antioxidants, such as ascorbic acid, cysteine hydrochloride, sodium bisulfate, sodium metabisulfite, sodium sulfite and the like; oil-soluble antioxidants, such as ascorbyl palmitate, butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), lecithin, propyl gallate, alpha-tocopherol, and the like; and metal chelating agents, such as citric acid, ethylenediamine tetra acetic acid (EDTA), sorbitol, tartaric acid, phosphoric acid, and the like.
[0060] Compositions containing novel Rifaximin form RV-A disclosed herein include those suitable for oral, nasal, topical (including buccal and sublingual), rectal, vaginal, aerosol and/or parenteral administration. The compositions may conveniently be presented in unit dosage form and may be prepared by any methods well known in the art of pharmacy. The amount of active ingredient which can be combined with a carrier material to produce a single dosage form will vary depending upon the host being treated, the particular mode of administration. The amount of active ingredient which can be combined with a carrier material to produce a single dosage form will generally be that amount of the compound which produces a therapeutic effect Generally, out of 100 % , this amount will range from about 1 % to about 99 % of active ingredient, preferably from about 5 % to about 70 %, most preferably from about 10 % to about 60 %.
[0061] Methods of preparing these compositions include the step of bringing into association the novel Rifaximin polymorph with the carrier and, optionally, one or more accessory ingredients. In general, the formulations are prepared by uniformly and intimately bringing into association the Rifaximin polymorph with liquid carriers, or finely divided solid carriers, or both, and then, if necessary, shaping the product [0062] Compositions suitable for oral administration may be in the form of capsules, sachets, pills, tablets, lozenges, powders, granules, or as a solution or a suspension in an aqueous or non-aqueous liquid, or as an oil-in-water or water-in-oil liquid emulsion, or as an elixir or syrup, or as pastilles and the like, each containing a predetermined amount of the Rifaximin polymorph as an active ingredient A compound may also be administered as a bolus, electuary or paste.
[0063] A tablet may be made by compression or moulding, optionally with one or more accessory ingredients. Compressed tablets may be prepared using binder such as gelatin or hydroxypropylmethyl cellulose and the like; lubricant; inert diluent; preservative; dis-integrant such as sodium starch glycolate or cross-linked sodium carboxymethyl cellulose and the like; surface-active or dispersing agent. Moulded tablets may be made by moulding a mixture of the powdered active ingredient moistened with an inert liquid diluent in a suitable machine.
[0064] The tablets, and other solid dosage forms of the pharmaceutical compositions described herein, may optionally be scored or prepared with coatings and shells, such as enteric coatings and other coatings well known in the pharmaceutical- formulating art They may also be formulated so as to provide slow or controlled release of the active ingredient therein using, for example, hydroxypropylmethyl cellulose in varying proportions to provide the desired release profile, other polymer matrices, liposomes and/ or microspheres.
[0065] An embodiment of the present invention provides the novel polymorphic form RV-A of Rifaximin described herein characterized by a PXRD diffractogram comprising peaks, in terms of degrees 2-theta (+/- 0.20 degree theta) at approximately 5.94, 7.32, 7.92, 8.56 and 19.01.
[00661 An embodiment of the present invention provides the novel polymorphic form RV-A of Rifaximin described herein characterized by a 1 % KBr FITR spectrum comprising peaks, in terms of cm-1, at approximately 3424, 2920, 1725, 1648 and 1229. [0067] An embodiment of the present invention provides a process for the preparation of a polymorphic form RV-A of Rifaximin, the process comprising: a. Reacting rifamycin O with 2-amino-4-methylpyridine in a suitable solvent or a mixture of solvents, for a time between 2 - 10 hours and at a temperature between 25°C to 75°C to provide crude Rifaximin. b. The resulting crude Rifaximin is purified by dissolving alcohol preferable ethyl alcohol, at a temperature between 35°C and 75°C, followed by crystallization by addition of water. The resulting suspension is stirred at a temperature between 50°C and 0°C for a duration between 2 and 24 hours. c. The suspension is filtered and the obtained solid is washed with water and dried under vacuum, optionally in the presence of a drying agent, at a temperature between room temperature and 75°C for a time between 2 and 24 hours.
[0068] An embodiment of the present invention provides a pharmaceutical composition as an oral dosage form, preferably in the form of a tablet [0069] An embodiment of the present invention provides a pharmaceutical composition in the form of tablets comprising i) Rifaximin RV-A, ii) pharmaceutically acceptable carriers, and optionally iii) a film forming coating agent.
[0070] The pharmaceutically acceptable carriers comprise sugars, such as lactose, glucose and sucrose; starches, such as com starch and potato starch; cellulose and its derivatives, such as hydroxypropyl methylcellulose (hypromellose), sodium carboxymethyl cellulose, carboxymethyl cellulose, microcrystalline cellulose, ethyl cellulose, sodium starch glycolate and cellulose acetate; powdered tragacanth; malt; gelatin; talc; glycols, such as propylene glycol; polyols, such as glycerin, sorbitol,
mannitol and polyethylene glycol; esters, such as ethyl oleate and ethyl laurate; agar; buffering agents, such as magnesium hydroxide and aluminium hydroxide; lubricants, such as Magnesium stearate, Zinc stearate, Calcium stearate, Sodium stearyl fumarate, Vegetable hydrogenated oil and Glyceryl palmitostearate; Disintegrants such as, Sodium starch glycolate and Crospovidone; Surfactant, such as Sodium lauryl sulfate and Polyethylene glycols; Chelating agent, such as disodium EDTA; Glidant, such as colloidal anhydrous silica and Talc; coating agents; coloring agents; sweetening, flavoring and perfuming agents; pyrogen- free water; and other non-toxic compatible substances employed in pharmaceutical formulations.
[0071] An embodiment of the present invention provides a pharmaceutical composition comprising the novel polymorphic form RV-A of Rifaximin characterized by a PXRD diffractogram comprising peaks, in terms of degrees 2-theta (+/- 0.20 degree theta) at approximately 5.94, 7.34, 7.93, 8.63, 14.49 and 22.47.
[0072] An embodiment of the present invention provides a pharmaceutical composition comprising the novel polymorphic form RV-A of Rifaximin which is stable over 24 months even when maintained at 30°Cand 75% relative humidity characterized by a PXRD diffractogram comprising peaks, in terms of degrees 2-theta (+/- 0.20 degree theta) at approximately 5.92, 7.35, 7.92, 8.60, 14.49 and 22.51.
[0073] Although various embodiments of the invention are disclosed herein, many adaptations and modifications may be made within the scope of the invention in accordance with the common general knowledge of those skilled in this art Such modifications include the substitution of known equivalents for any aspect of the invention in order to achieve the same result in substantially the same way. Numeric ranges are inclusive of the numbers defining the range. Furthermore, numeric ranges are provided so that the range of values is recited in addition to the individual values within the recited range being specifically recited in the absence of the range. The word "comprising" is used herein as an open-ended term, substantially equivalent to the phrase "including, but not limited to", and the word "comprises" has a corresponding meaning. As used herein, the singular forms "a", "an" and "the" include plural references unless the context clearly dictates otherwise. Thus, for example, reference to "a thing" includes more than one such thing. Citation of references herein
is not an admission that such references are prior art to the present invention. Furthermore, material appearing in the background section of the specification is not an admission that such material is prior art to the invention.
EXAMPLES
[0074] The following examples are illustrative of some of the embodiments of the invention described herein. These examples do not limit the spirit or scope of the invention in any way.
[0075] Characterisation: The novel polymorphic form of Rifaximin was characterised by one or more of PXRD, FT-IR, 1H NMR.
[0076] Powder X-ray diffraction (PXRD) analysis was performed using Bruker D8 Advance LYNXEYE XE-T diffractometer.
[0077] 1H NMR spectrum Analysis: 1H NMR was recorded on Bruker at 400 MHz, 300K and solution of the sample was made in CDCl3.
[0078] Fourier Transform Infrared (FTIR) Analysis: The FTIR spectrum was collected at 4 cm-1 resolution using a Perkin Elmer FT IR spectrum 100, Model No. C 79114 SPLOD.
Preparation of Rifaximin
[0079] To a solution of water and ethyl alcohol (100 mL, 1:1) was added rifamycin O (37.5 g) and 2-amino-4-methylpyridine (16.5 g). The reaction mass was heated at 50°C for 6 hours, then cooled to 25°C and acidified by hydrochloric acid to a pH of 2. The precipitate was filtered to provide crude Rifaximin. Crude Rifaximin (25 g) was suspended in ethyl alcohol (50 mL) and heated at 55°C so as to obtain a clear solution. To this solution was added water (20 mL) and allowed to stand to obtain crystallisation. The temperature was reduced to 0°C and maintained for 4 hours. The suspension was filtered, washed with water and dried under vacuum to obtain Rifaximin (20 g). The obtained Rifaximin form RV-A was characterised by powder X- ray diffractogram showing significant peaks at diffraction angles 2Θ of 5.94°; 7.32°; 7.92°
Mass (m/e): 786.1
1H NMR (400 Hz, CDCl3): δ 14.62 (s, 1H); 8.44-8.46 (d, 1H); 7.36 (s, 1H); 7.06-7.08 (s, 1H); 6.72-6.81 (dd, 1H); 6.31-6.34 (m, 1H); 5.99-6.07 (m, 2H); 4.94-5.00 (dd, 1H); 4.84- 4.88 (d, 1H); 3.57-3.67 (m, 2H); 3.27 (s, 1H); 2.96 (d, 3H); 2.82-2.85 (s, 1H); 2.61 (s, 3H); 2.27 (s, 4H); 1.93-1.99 (t, 9H); 1.54-1.56 (d, 1H); 1.25-1.28 (m, 1H); 1.10-1.13 (m, 1H); 0.90-0.92 (d, 3H); 0.70-0.72 (d, 3H); 0.61-0.63 (d, 3H); 0.11-0.13 (d, 3H).
Preparation of Tablet composition:
[0080] A Rifaximin composition comprising the novel polymorphic form of Rifaximin namely RV-A, microcrystalline cellulose, sodium starch glycolate, polyethylene glycol 4000, hypromellose, disodium EDTA and purified water, was mixed in a rapid mixer granulator for 15 minutes at slow speed. The blended wet mass was dried in a fluid bed dryer to obtain granules that had a moisture content of up to 4% . The granules obtained were mixed with microcrystalline cellulose, sodium starch glycolate, purified talc, colloidal anhydrous silica, glyceryl palmito stearate and magnesium stearate in a blender. The final blend was compressed on a press and the resulting tablets were film coated with instacoat Universal A05R00959 such that the resulting tablets each contain Rifaximin 555.5 mg including 1% overage and the overall tablet weight is 980 mg ±5% .
Claims
1. A polymorphic form RV-A of Rifaximin.
2. The polymorphic form RV-A of Rifaximin of claim 1 characterized by a PXRD diffractogram comprising peaks, in terms of degrees 2-theta, at approximately 5.94, 7.32, 7.92, 8.56 and 19.01.
3. The polymorphic form RV-A of Rifaximin of claim 1 characterized by a PXRD diffractogram as depicted in Figure 1.
4. The polymorphic form RV-A of Rifaximin of claiml characterized by a 1 % KBr FTIR spectrum comprising peaks, in terms of cm-1, at approximately 3424, 2920, 1725, 1648 and 1229.
5. The polymorphic form RV-A of Rifaximin of claiml characterized by a FTIR spectrum as depicted in Figure 2.
6. A process for the preparation of a polymorphic form RV-A of Rifaximin as claimed in claim 1, the process comprising: i. reacting rifamycin O with 2-amino-4-methylpyridine in a suitable solvent or a mixture of solvents, for a time between 2 - 10 hours and at a temperature between 25°C to 75°C to provide crude Rifaximin, ii. The resulting crude Rifaximin is purified by dissolving alcohol preferable ethyl alcohol, at a temperature between 35°C and 75°C, followed by crystallization by addition of water. The resulting suspension is stirred at a temperature between 50°C and 0°C for a duration between 2 and 24 hours, iii. The suspension is filtered and the obtained solid is washed with water and dried under vacuum, optionally in the presence of a drying agent, at a temperature between room temperature and 75°C for a time between 2 and 24 hours.
7. Pharmaceutical composition in the form of tablets comprising i) Rifaximin RV-A as claimed in claim 1, ii) pharmaceutically acceptable carriers, and optionally iii) a film forming coating agent
8. The pharmaceutical composition according to Claim 7, wherein the pharmaceutically acceptable carriers comprise one or more cellulose and its derivatives, selected from hydroxypropyl methylcellulose (hypromellose), sodium carboxymethyl cellulose, carboxymethyl cellulose, microcrystalline cellulose, ethyl cellulose, sodium starch glycolate, cellulose acetate; polyols selected from glycerin, sorbitol, mannitol, polyethylene glycol; lubricants selected from magnesium stearate, calcium stearate, sodium stearyl fumarate, hydrogenated vegetable oils, mineral oils and glyceryl palmitostearate; disintegrants, selected from, sodium starch glycolate, crospovidone and croscarmellose sodium; surfactant selected from sodium lauryl sulfate and polyethylene glycols; chelating agent selected from disodium EDTA; glidant selected from colloidal anhydrous silica and talc; coating solvents selected from purified water and isopropyl alcohol; coating agents; colouring agents; sweetening agents, flavouring and perfuming agents.
9. The pharmaceutical composition of claim 7 characterized by a PXRD diffractogram comprising peaks, in terms of degrees 2-theta, at approximately 5.94, 7.34, 7.93, 8.63, 14.49 and 22.47.
10. The pharmaceutical composition of claim 7 characterized by a PXRD diffractogram as depicted in Figure 3.
11. A process for the preparation of a tablet containing Rifaximin RV-A of claim 1, comprising the steps of: i. providing novel polymorph of Rifaximin RV-A and optionally one or more further excipients,
ii. optionally granulating the mixture of step (i) and optionally one or more further excipients, iii. compressing the mixture from step (i) or the granulates from step (ii) and optionally further excipients into a tablet
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN202021020567 | 2020-05-15 | ||
IN202021020567 | 2020-05-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2021229480A1 true WO2021229480A1 (en) | 2021-11-18 |
Family
ID=78525447
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2021/054078 WO2021229480A1 (en) | 2020-05-15 | 2021-05-13 | Polymorph of rifaximin, process for the preparation thereof and pharmaceutical composition containing rifaximin |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2021229480A1 (en) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005044823A2 (en) * | 2003-11-07 | 2005-05-19 | Alfa Wassermann S.P.A. | Polymorphous forms of rifaximin as antibiotics |
WO2008035109A1 (en) * | 2006-09-22 | 2008-03-27 | Cipla Limited | Rifaximin |
WO2011156897A2 (en) * | 2010-06-16 | 2011-12-22 | Apotex Pharmachem Inc. | Polymorphic forms of rifaximin |
WO2013185211A1 (en) * | 2012-06-13 | 2013-12-19 | Apotex Pharmachem Inc. | Polymorphic forms of rifaximin |
-
2021
- 2021-05-13 WO PCT/IB2021/054078 patent/WO2021229480A1/en active Application Filing
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005044823A2 (en) * | 2003-11-07 | 2005-05-19 | Alfa Wassermann S.P.A. | Polymorphous forms of rifaximin as antibiotics |
WO2008035109A1 (en) * | 2006-09-22 | 2008-03-27 | Cipla Limited | Rifaximin |
WO2011156897A2 (en) * | 2010-06-16 | 2011-12-22 | Apotex Pharmachem Inc. | Polymorphic forms of rifaximin |
WO2013185211A1 (en) * | 2012-06-13 | 2013-12-19 | Apotex Pharmachem Inc. | Polymorphic forms of rifaximin |
Non-Patent Citations (2)
Title |
---|
LIAN YU: "Amorphous pharmaceutical solids: preparation, characterization and stabilization", ADVANCED DRUG DELIVERY REVIEWS, vol. 48, 2001, pages 27 - 42, XP009065056, DOI: 10.1016/S0169-409X(01)00098-9 * |
VIPPAGUNTA S R, BRITTAIN H G, GRANT D J W: "CRYSTALLINE SOLIDS", ADVANCED DRUG DELIVERY REVIEWS, ELSEVIER, AMSTERDAM , NL, vol. 48, no. 01, 1 January 2001 (2001-01-01), Amsterdam , NL , pages 03 - 26, XP001181963, ISSN: 0169-409X, DOI: 10.1016/S0169-409X(01)00097-7 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10702505B2 (en) | Rifaximin | |
KR101663491B1 (en) | Rifaximin powder, process for preparing the same and controlled release compositions containing said Rifaximin useful for obtaining a long-lasting effect | |
US8883795B2 (en) | Polymorphic forms of Rifaximin | |
US11739099B2 (en) | Polymorphic mixture of Rifaximin and its use for the preparation of solid formulations | |
EP1940834A2 (en) | Amorphous and crystalline forms of 9-hydroxy-risperidone (paliperidone) | |
CN111164085B (en) | Eutectic of rebamipillin and eutectic of rebamipillin monosuccinate, preparation method, composition and application thereof | |
WO2022223027A1 (en) | Tolebrutinib crystal form, amorphous form, preparation method therefor and use thereof | |
EP3546464B1 (en) | Preparation and use of crystalline form tau of rifaximin solvated with degme | |
WO2022076779A1 (en) | Solid state forms of trilaciclib and of trilaciclib salts | |
EP1848420A2 (en) | Polymorphic forms of a gabaa agonist | |
WO2021229480A1 (en) | Polymorph of rifaximin, process for the preparation thereof and pharmaceutical composition containing rifaximin | |
AU2003232113A1 (en) | Novel crystalline forms of gatifloxacin | |
JP2007527434A (en) | Amorphous tacrolimus and its preparation | |
CN112979652B (en) | Isopropanol bridged purine azole compound or pharmaceutically acceptable salt thereof, and preparation method and application thereof | |
PL219565B1 (en) | Anhydrous aripiprazole D crystals, method of their preparation, pharmaceutical composition and pharmaceutical solid oral preparation containing D crystals of anhydrous aripiprazole | |
EP1645274A1 (en) | Process for making gatifloxacin form omega | |
EP2133352A2 (en) | Crystal form of 9-hydroxy-risperidone (paliperidone) | |
EP2133351A2 (en) | Crystal form of 9-hydroxy-risperidone (paliperidone) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21803301 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 21803301 Country of ref document: EP Kind code of ref document: A1 |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 21803301 Country of ref document: EP Kind code of ref document: A1 |